Stay updated on Standard vs Double Dose Dolutegravir in HIV/TB Clinical Trial
Sign up to get notified when there's something new on the Standard vs Double Dose Dolutegravir in HIV/TB Clinical Trial page.

Latest updates to the Standard vs Double Dose Dolutegravir in HIV/TB Clinical Trial page
- ChecktodayChange DetectedThe page’s version label was updated from Revision: v3.6.4 to Revision: v3.6.5. This is a minor release tag update rather than a modification to the study content or layout.SummaryDifference0.1%

- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedThe page now displays a newer site revision, updating from v3.6.3 to v3.6.4, indicating a software deployment. The update is limited to system metadata and does not modify study content or user-facing features.SummaryDifference0.1%

- Check22 days agoNo Change Detected
- Check36 days agoChange DetectedFooter shows Revision: v3.6.3, replacing v3.6.2, representing a small behind-the-scenes update to the site.SummaryDifference0.1%

- Check43 days agoChange DetectedRevision updated from v3.6.0 to v3.6.2, indicating a newer build of the page. This is a backend/version change rather than content-level updates.SummaryDifference0.1%

- Check58 days agoChange DetectedAdded sections for How to Read a Study Record, Common Questions, and How to Join a Study, and displayed enrollment as No longer looking for participants, while updating the intervention labeling and revision tag from v3.5.5 to v3.6.0, reflecting an update to how the study details are presented and navigated.SummaryDifference0.4%

- Check65 days agoChange DetectedThe page footer's revision tag was updated to v3.5.5, replacing the previous v3.5.4; this reflects a software/patch update rather than a change to study information.SummaryDifference0.1%

Stay in the know with updates to Standard vs Double Dose Dolutegravir in HIV/TB Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Standard vs Double Dose Dolutegravir in HIV/TB Clinical Trial page.